As alpelisib and everolimus specifically target the PI3K/Akt/mTOR pathway, we performed targeted next-generation sequencing to test for mutations in 64 cancer genes, including the PI3K pathway genes (Supplementary Materials Table S2). The gene discussed is PIK3CA; the disease is cancer.